$TSOI
THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Stock $tsoi

$tsoi Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000149315222032787 Filed on November 17, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$8.580K	$74.54K	$57.29K
YoY Change	-80.57%	30.11%	404.76%
Cost Of Revenue	$46.00K	$8.790K	$12.43K
YoY Change	207.69%	-29.28%	356.99%
Gross Profit	-$37.42K	$65.75K	$44.86K
YoY Change	-228.11%	46.57%	419.81%
Gross Profit Margin	-436.13%	88.21%	78.3%
Selling, General & Admin	$457.2K	$509.9K	$715.1K
YoY Change	36.05%	-28.69%	95.85%
% of Gross Profit		775.5%	1593.96%
Research & Development	$264.0K	$275.1K	$31.82K
YoY Change	-56.8%	764.46%	-76.24%
% of Gross Profit		418.35%	70.93%
Depreciation & Amortization	$49.96K	$87.54K	$4.360K
YoY Change	450.22%	1907.8%	146.33%
% of Gross Profit		133.14%	9.72%
Operating Expenses	$721.2K	$785.0K	$746.9K
YoY Change	-23.86%	5.1%	49.66%
Operating Profit	-$758.6K	-$719.2K	-$702.0K
YoY Change	-17.36%	2.45%	43.15%
Interest Expense	-$70.40K	$167.4K	-$112.8K
YoY Change	-82.56%	-248.39%	1076.12%
% of Operating Profit
Other Income/Expense, Net	-$110.6K	-$226.4K	$0.00
YoY Change
Pretax Income	-$939.7K	-$945.7K	-$814.8K
YoY Change	-28.9%	16.06%	62.96%
Income Tax	$0.00	$800.00
% Of Pretax Income
Net Earnings	-$939.7K	-$946.5K	-$814.8K
YoY Change	-28.95%	16.16%	62.96%
Net Earnings / Revenue	-10951.86%	-1269.72%	-1422.24%
Basic Earnings Per Share		$0.00	$0.00
Diluted Earnings Per Share	$0.00	-$368.90	-$359.30
COMMON SHARES
Basic Shares Outstanding	2.608B shares	2.566B shares	2.267B shares
Diluted Shares Outstanding		2.566B shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$18.04K	$94.25K	$62.26K
YoY Change	-80.82%	51.38%	-78.1%
Cash & Equivalents	$18.04K	$94.25K	$62.26K
Short-Term Investments
Other Short-Term Assets	$223.4K	$343.0K	$312.4K
YoY Change	-76.96%	9.8%	122.06%
Inventory	$42.43K	$44.94K	$61.40K
Prepaid Expenses	$62.66K
Receivables	$25.40K	$42.38K	$21.49K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$309.2K	$524.6K	$457.6K
YoY Change	-72.39%	14.65%	5.85%
LONG-TERM ASSETS
Property, Plant & Equipment	$273.1K	$354.1K	$350.4K
YoY Change	-3.85%	1.07%	6574.1%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.015M	$3.298M	$221.9K
YoY Change	986.07%	1386.46%	23.17%
Total Long-Term Assets	$3.296M	$3.668M	$707.7K
YoY Change	453.28%	418.24%	281.71%
TOTAL ASSETS
Total Short-Term Assets	$309.2K	$524.6K	$457.6K
Total Long-Term Assets	$3.296M	$3.668M	$707.7K
Total Assets	$3.606M	$4.192M	$1.165M
YoY Change	110.14%	259.77%	88.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$402.0K	$364.0K	$361.7K
YoY Change	2.02%	0.64%	11.54%
Accrued Expenses	$531.8K	$552.2K	$475.5K
YoY Change	9.15%	16.15%	-15.8%
Deferred Revenue
YoY Change
Short-Term Debt	$1.054M	$1.061M	$1.065M
YoY Change	0.9%	-0.33%	10.2%
Long-Term Debt Due	$4.640K	$4.640K	$4.070K
YoY Change	14.0%	14.0%
Total Short-Term Liabilities	$2.210M	$2.395M	$2.255M
YoY Change	-11.46%	6.19%	14.72%
LONG-TERM LIABILITIES
Long-Term Debt	$10.51K	$11.64K	$16.63K
YoY Change	-32.32%	-30.01%	132.59%
Other Long-Term Liabilities	$0.00	$2.150K	$15.07K
YoY Change	-100.0%	-85.73%	-62.97%
Total Long-Term Liabilities	$10.51K	$13.79K	$31.70K
YoY Change	-56.82%	-56.5%	-33.75%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.210M	$2.395M	$2.255M
Total Long-Term Liabilities	$10.51K	$13.79K	$31.70K
Total Liabilities	$2.221M	$2.409M	$2.287M
YoY Change	-11.9%	5.32%	13.57%
SHAREHOLDERS EQUITY
Retained Earnings	-$17.67M	-$16.73M
YoY Change	26.28%
Common Stock	$2.617M	$2.588M
YoY Change	13.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.385M	$1.784M	-$1.122M
YoY Change
Total Liabilities & Shareholders Equity	$3.606M	$4.192M	$1.165M
YoY Change	110.14%	259.77%	88.66%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$939.7K	-$946.5K	-$814.8K
YoY Change	-28.95%	16.16%	62.96%
Depreciation, Depletion And Amortization	$49.96K	$87.54K	$4.360K
YoY Change	450.22%	1907.8%	146.33%
Cash From Operating Activities	-$365.1K	-$201.9K	-$127.2K
YoY Change	142.03%	58.71%	-54.63%
INVESTING ACTIVITIES
Capital Expenditures	-$200.0K	$0.00	-$23.20K
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change
Cash From Investing Activities	$200.0K	$0.00	-$23.20K
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$60.00K
YoY Change			-89.17%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	88.86K	98.85K	158.9K
YoY Change	-51.34%	-37.78%	-70.19%
NET CHANGE
Cash From Operating Activities	-365.1K	-201.9K	-127.2K
Cash From Investing Activities	200.0K	0.000	-23.20K
Cash From Financing Activities	88.86K	98.85K	158.9K
Net Change In Cash	-76.20K	-103.0K	8.470K
YoY Change	-339.85%	-1316.53%	-96.65%
FREE CASH FLOW
Cash From Operating Activities	-$365.1K	-$201.9K	-$127.2K
Capital Expenditures	-$200.0K	$0.00	-$23.20K
Free Cash Flow	-$165.1K	-$201.9K	-$104.0K
YoY Change	9.43%	94.11%	-62.9%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001419051
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	TSOI	Relief Of Derivative Liabilities ReliefOfDerivativeLiabilities		usd
	TSOI	Stock Issued During Period Value New Issues Preferred Stock StockIssuedDuringPeriodValueNewIssuesPreferredStock		usd
CY2022Q3	TSOI	Stock Issued During Period Value New Issues Preferred Stock StockIssuedDuringPeriodValueNewIssuesPreferredStock		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
	us-gaap	Proceeds From Other Deposits ProceedsFromOtherDeposits		usd
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired		usd
	TSOI	Common Stock Issued For License Value CommonStockIssuedForLicenseValue		usd
CY2021Q4	us-gaap	Regulatory Assets RegulatoryAssets		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Entity File Number EntityFileNumber	000-54554
	dei	Entity Registrant Name EntityRegistrantName	Therapeutic Solutions International, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-1226465
	dei	Entity Address Address Line1 EntityAddressAddressLine1	701 Wild Rose Lane
	dei	Entity Address City Or Town EntityAddressCityOrTown	Elk City
	dei	Entity Address State Or Province EntityAddressStateOrProvince	ID
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	83525
	dei	City Area Code CityAreaCode	(760)
	dei	Local Phone Number LocalPhoneNumber	295-7208
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	2608288008	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	94246	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	94036	usd
CY2022Q3	us-gaap	Restricted Cash RestrictedCash	11003	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	10223	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	42382	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	16613	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	44943	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	39817	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	332015	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	959307	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	524589	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	1119996	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	354135	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	284024	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	15071	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	34184	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3298465	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	277571	usd
CY2022Q3	us-gaap	Assets Assets	4192260	usd
CY2021Q4	us-gaap	Assets Assets	1715775	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	363984	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	394035	usd
CY2022Q3	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	7239	usd
CY2021Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	9791	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	552240	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	487208	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	12918	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	25374	usd
CY2022Q3	us-gaap	Notes Payable Current NotesPayableCurrent	4638	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	4071	usd
CY2022Q3	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	210242	usd
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	225800	usd
CY2022Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	79008	usd
CY2021Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	79200	usd
CY2022Q3	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	982203	usd
CY2021Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	965211	usd
CY2022Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	392561	usd
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	531525	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2394791	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2496415	usd
CY2022Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	11641	usd
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	15532	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2153	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8810	usd
CY2022Q3	us-gaap	Liabilities Liabilities	2408585	usd
CY2021Q4	us-gaap	Liabilities Liabilities	2520757	usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	2	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3500000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3500000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2588063537	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2588063537	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2311123860	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2311123860	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	2588064	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	2311125	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	15948999	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	10899139	usd
CY2022Q3	us-gaap	Stockholders Equity Note Subscriptions Receivable StockholdersEquityNoteSubscriptionsReceivable	21000	usd
CY2021Q4	us-gaap	Stockholders Equity Note Subscriptions Receivable StockholdersEquityNoteSubscriptionsReceivable	21000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-16732388	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-13994246	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	1783675	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-804982	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4192260	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1715775	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	74541	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	57291	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	198188	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	101796	usd
CY2022Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8790	usd
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	12431	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	33437	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	27598	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	65751	usd
CY2021Q3	us-gaap	Gross Profit GrossProfit	44860	usd
	us-gaap	Gross Profit GrossProfit	164751	usd
	us-gaap	Gross Profit GrossProfit	74198	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	204838	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	31271	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	388561	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	96722	usd
CY2022Q3	us-gaap	Labor And Related Expense LaborAndRelatedExpense	110108	usd
CY2021Q3	us-gaap	Labor And Related Expense LaborAndRelatedExpense	83968	usd
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	336926	usd
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	319198	usd
CY2022Q3	us-gaap	Professional Fees ProfessionalFees	88158	usd
CY2021Q3	us-gaap	Professional Fees ProfessionalFees	107514	usd
	us-gaap	Professional Fees ProfessionalFees	317284	usd
	us-gaap	Professional Fees ProfessionalFees	224844	usd
CY2022Q3	us-gaap	Legal Fees LegalFees	106795	usd
CY2021Q3	us-gaap	Legal Fees LegalFees	492295	usd
	us-gaap	Legal Fees LegalFees	266158	usd
	us-gaap	Legal Fees LegalFees	636193	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	275071	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	31815	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1177123	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	183597	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	784970	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	746863	usd
	us-gaap	Operating Expenses OperatingExpenses	2486052	usd
	us-gaap	Operating Expenses OperatingExpenses	1460554	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-719219	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-702003	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2321301	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1386356	usd
CY2022Q3	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative	26867	usd
CY2021Q3	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative	45006	usd
	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative	136583	usd
	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative	477559	usd
CY2022Q3	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-32205	usd
CY2021Q3	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	53624	usd
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2565663048	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2267469428	shares
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	233303	usd
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	624376	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	167371	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	121414	usd
	us-gaap	Interest Expense InterestExpense	512761	usd
	us-gaap	Interest Expense InterestExpense	399425	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-226443	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-112796	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-416041	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-252608	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-945662	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-814799	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2737342	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1638964	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	800	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	800	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-946462	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-814799	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2738142	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1638964	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2501116667	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2253155062	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-1778099	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	558221	usd
	TSOI	Stock Issued During Period Value For Prepaid Fees StockIssuedDuringPeriodValueForPrepaidFees	547450	usd
	TSOI	Stock Issued During Period Values For Accrued Salaries StockIssuedDuringPeriodValuesForAccruedSalaries	239800	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	285499	usd
	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	58900	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	303159	usd
	TSOI	Relief Of Derivative Liabilities ReliefOfDerivativeLiabilities	302365	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1638964	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-1121669	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-1296529	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	386821	usd
CY2021Q3	TSOI	Stock Issued During Period Value For Prepaid Fees StockIssuedDuringPeriodValueForPrepaidFees	347950	usd
CY2021Q3	TSOI	Stock Issued During Period Values For Accrued Salaries StockIssuedDuringPeriodValuesForAccruedSalaries	40800	usd
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	60000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	35700	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	56710	usd
CY2021Q3	TSOI	Relief Of Derivative Liabilities ReliefOfDerivativeLiabilities	61678	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-814799	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-1121669	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-804982	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	508078	usd
	TSOI	Stock Issued During Period Value For Prepaid Fees StockIssuedDuringPeriodValueForPrepaidFees	242320	usd
	TSOI	Stock Issued During Period Values For Accrued Salaries StockIssuedDuringPeriodValuesForAccruedSalaries	29999	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	445000	usd
	TSOI	Stock Issued During Period Value For License StockIssuedDuringPeriodValueForLicense	3107570	usd
	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	50400	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	943432	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2738142	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	1783675	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	2212440	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	2212440	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	100878	usd
CY2022Q3	TSOI	Stock Issued During Period Value For Prepaid Fees StockIssuedDuringPeriodValueForPrepaidFees	93500	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	50400	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	272919	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-946462	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	1783675	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	1783675	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2738142	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1638964	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	311078	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	416321	usd
	TSOI	Share Based Compensation To Related Parties ShareBasedCompensationToRelatedParties	197000	usd
	TSOI	Share Based Compensation To Related Parties ShareBasedCompensationToRelatedParties	141900	usd
	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative	136583	usd
	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative	477559	usd
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	233303	usd
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	624376	usd
	TSOI	Amortization Of Prepaid Stock Based Compensation AmortizationOfPrepaidStockBasedCompensation	868089	usd
	TSOI	Amortization Of Prepaid Stock Based Compensation AmortizationOfPrepaidStockBasedCompensation	91646	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	461058	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	353320	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	191192	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4943	usd
	us-gaap	Depreciation Depreciation	3489	usd
	us-gaap	Depreciation Depreciation	4051	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	25769	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	19047	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5126	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	56005	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-73807	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-88789	usd
	TSOI	Increase Decrease In Right Of Use Asset IncreaseDecreaseInRightOfUseAsset	19113	usd
	TSOI	Increase Decrease In Right Of Use Asset IncreaseDecreaseInRightOfUseAsset	18531	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-30051	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	59178	usd
	TSOI	Increase Decrease In Account Payable Related Parties IncreaseDecreaseInAccountPayableRelatedParties	-2552	usd
	TSOI	Increase Decrease In Account Payable Related Parties IncreaseDecreaseInAccountPayableRelatedParties	42	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	139405	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	132549	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-19113	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-18531	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-653242	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-568094	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	260565	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	200000	usd
	us-gaap	Proceeds From Other Deposits ProceedsFromOtherDeposits	4015	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-200000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-256550	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	2444	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	3503	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	415000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	353750	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	3324	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	969	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	445000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	285499	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	854232	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	634777	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	990	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-189867	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	104259	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	262349	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	105249	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	72482	usd
	us-gaap	Interest Paid Net InterestPaidNet	2357	usd
	us-gaap	Interest Paid Net InterestPaidNet	2311	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	800	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	800	usd
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	30500	usd
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	22250	usd
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	415000	usd
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	353750	usd
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	943431	usd
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	605525	usd
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	21671	usd
	TSOI	Common Stock Issued For Prepaid Fees Value CommonStockIssuedForPrepaidFeesValue	242320	usd
	TSOI	Common Stock Issued For Prepaid Fees Value CommonStockIssuedForPrepaidFeesValue	547450	usd
	TSOI	Common Stock Issued For Accrued Salaries Value CommonStockIssuedForAccruedSalariesValue	29999	usd
	TSOI	Common Stock Issued For Accrued Salaries Value CommonStockIssuedForAccruedSalariesValue	239800	usd
	TSOI	Accrued Interest Added To Principal AccruedInterestAddedToPrincipal	19436	usd
	TSOI	Accrued Interest Added To Principal AccruedInterestAddedToPrincipal	19434	usd
	TSOI	Common Stock Issued For License Value CommonStockIssuedForLicenseValue	3107570	usd
	us-gaap	Stock Issued1 StockIssued1	50400	usd
	us-gaap	Stock Issued1 StockIssued1	58900	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	94246	usd
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	62259	usd
CY2022Q3	us-gaap	Restricted Cash RestrictedCash	11003	usd
CY2021Q3	us-gaap	Restricted Cash RestrictedCash	10223	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	105249	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72482	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80A_eus-gaap--NatureOfOperations_zbpDAWqwMSr7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 – <span id="xdx_820_zzRZYRzm5UYa">Organization and Business Description</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Therapeutic Solutions International, Inc. (“TSI” or the “Company”) was organized <span id="xdx_90A_edei--EntityIncorporationDateOfIncorporation_c20220101__20220930" title="Entity incorporation date">August 6, 2007</span> under the name <span id="xdx_90F_edei--EntityInformationFormerLegalOrRegisteredName_c20220101__20220930" title="Entity information, former legal or registered name">Friendly Auto Dealers, Inc.,</span> under the laws of the State of Nevada. In the first quarter of 2011 the Company changed its name from Friendly Auto Dealers, Inc. to Therapeutic Solutions International, Inc., and acquired Splint Decisions, Inc., a California corporation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business Description</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently, the Company is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Activating one’s immune system is now an accepted method to treat certain cancers, reduce recovery time from viral or bacterial infections and to prevent illness. Additionally, inhibiting one’s immune system is vital for reducing inflammation, autoimmune disorders and allergic reactions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TSOI is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, traumatic brain injury, lung pathologies, and for daily health.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cellular Division</b> – TSOI obtained exclusive rights to a patented adult stem cell for development of therapeutics in the area of chronic traumatic encephalopathy (CTE) and traumatic brain injury (TBI) and Lung Pathology (LP).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The stem cell licensed, termed “JadiCell” is unique in that it possesses features of mesenchymal stem cells, however, outperforms these cells in terms of a) enhanced growth factor production; b) augmented ability to secrete exosomes; and c) superior angiogenic and neurogenic ability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chronic Traumatic Encephalopathy (CTE) is caused by repetitive concussive/sub-concussive hits to the head sustained over a period of years and is often found in football players. The condition is characterized by memory loss, impulsive/erratic behavior, impaired judgment, aggression, depression, and dementia. In many patients with CTE, it is anatomically characterized by brain atrophy, reduced mass of frontal and temporal cortices, and medial temporal lobe. TSOI has previously filed several patents in the area of CTE based on modulating the brain microenvironment to enhance receptivity of regenerative cells such as stem cells. On March 4, 2021 the Company received an IND Serial # 27377 for a clinical trial of 10 patients with CTE.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 4th, 2021, the Company announced clearance from the Food and Drug Administration (FDA) to initiate a Phase III pivotal trial for registration of the Company’s JadiCell™ universal donor stem cell as a treatment for COVID-19 associated lung failure under IND # 19757. In previous studies the Company has demonstrated the superior activity of JadiCell™ to other types of stem cells including bone marrow, adipose, cord blood, and placenta. Furthermore, the JadiCell™ was shown to be 100% effective in saving the lives of COVID-19 patients under the age of 85 in a double-blind placebo controlled clinical trial with patients in the ICU on a ventilator. In patients over the age of 85 the survival rate was 91%.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, the Company has filed data with the FDA, as part of IND #17448, which demonstrated that treatment of cancer patients with StemVacs™ resulted in enhanced activity of a type of immunological cell called “natural killer” cells, otherwise known as “NK cells.”</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has also developed an allogenic version of StemVacs and has filed patents to cover activating universal donor immune system cells called dendritic cells in a manner so that upon injection they reprogram the body’s NK cells.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most recently the Company announced filing of a patent for a new hybrid cell created by the Company capable of training the immune system to kill blood vessels feeding cancer but sparing healthy blood vessels. These discoveries are an extension of previous findings from the Company showing that StemVacs is capable of suppressing new blood vessel production.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 9, 2022, the Company filed an Investigational New Drug Application for Treatment of Chronic Obstructive Pulmonary Disease (COPD) Using JadiCell™ Universal Donor Adult Stem Cells under IND Serial # 28508.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30, 2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management does not expect existing cash as of September 30, 2022, to be sufficient to fund the Company’s operations for at least twelve months from the issuance date of these financial statements. These financial statements have been prepared on a going concern basis which assumed the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of September 30, 2022, the Company has incurred losses totaling $<span id="xdx_90F_eus-gaap--NetIncomeLoss_pn5n6_c20170101__20220930_z2bUxchw4Ek8" title="Net loss">16.7</span> million since inception, has not yet generated material revenue from operations, and will require additional funds to maintain its operations. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern within one year after the consolidated financial statements are issued. The Company’s ability to continue as a going concern is dependent upon its ability to generate future profitable operations and obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due. The Company intends to finance operating costs over the next twelve months through its existing financial resources and we may also raise additional capital through equity offerings, debt financings, collaborations and/or licensing arrangements. If adequate funds are not available on acceptable terms, we may be required to delay, reduce the scope of, or curtail, our operations. The accompanying consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2007-08-06
	dei	Entity Information Former Legal Or Registered Name EntityInformationFormerLegalOrRegisteredName	Friendly Auto Dealers, Inc.,
	us-gaap	Net Income Loss NetIncomeLoss	16700000	usd
	TSOI	Wholesale Purchase Price And Payments Description WholesalePurchasePriceAndPaymentsDescription	Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of $500,000 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retail
CY2022Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	0	usd
CY2021Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	0	usd
CY2022Q3	TSOI	Prepaid Consulting Current PrepaidConsultingCurrent	239646	usd
CY2021Q4	TSOI	Prepaid Consulting Current PrepaidConsultingCurrent	930893	usd
CY2022Q3	us-gaap	Prepaid Insurance PrepaidInsurance	1717	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	987	usd
CY2022Q3	TSOI	Prepaid Costs Current PrepaidCostsCurrent	90652	usd
CY2021Q4	TSOI	Prepaid Costs Current PrepaidCostsCurrent	27427	usd
CY2022Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	392561	usd
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	531525	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	15071	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	15071	usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	531525	usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues	576592	usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Net FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet	-482253	usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Period Increase Decrease FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease	-233303	usd
CY2022Q3	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	392561	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_847_eus-gaap--UseOfEstimates_zkOMKNs02Vf1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of Estimates</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	332015	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	959307	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	211919728	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	286251995	shares
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	17135	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	354135	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	284024	usd
	us-gaap	Depreciation Depreciation	3489	usd
	us-gaap	Depreciation Depreciation	3489	usd
	us-gaap	Depreciation Depreciation	4051	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	191192	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4943	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	24477	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3045453	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	129075	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	191192	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4943	usd
	us-gaap	Depreciation Depreciation	4051	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1177123	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	183597	usd
CY2022Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	10000	usd
	TSOI	Annual Interest Rate AnnualInterestRate	0.006	pure
	us-gaap	Restricted Cash Current Nature Of Restriction Description RestrictedCashCurrentNatureOfRestrictionDescription	This certificate matures on June 17, 2023, and is used as collateral for a Company credit card, pursuant to a security agreement dated June 20, 2011
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	374959	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	301159	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	20824	usd
CY2022Q3	TSOI	Prepaid Consulting Noncurrent PrepaidConsultingNoncurrent	13189	usd
CY2021Q4	TSOI	Prepaid Consulting Noncurrent PrepaidConsultingNoncurrent	108673	usd
CY2022Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	39823	usd
CY2021Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	39823	usd
CY2022Q3	us-gaap	Regulatory Assets RegulatoryAssets	200000	usd
CY2022Q3	TSOI	Licenses Noncurrent LicensesNoncurrent	3045453	usd
CY2021Q4	TSOI	Licenses Noncurrent LicensesNoncurrent	129075	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3298465	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	277571	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3261122	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	153552	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	215669	usd
CY2022Q3	us-gaap	Capital Units Authorized CapitalUnitsAuthorized	3505000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3500000000	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2588063537	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2588063537	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	2	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2	shares
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	6249	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	8612	usd

Files In Submission

Name	View Source	Status
0001493152-22-032787-index-headers.html	Edgar Link	pending
0001493152-22-032787-index.html	Edgar Link	pending
0001493152-22-032787.txt	Edgar Link	pending
0001493152-22-032787-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tsoi-20220930.xsd	Edgar Link	pending
tsoi-20220930_cal.xml	Edgar Link	unprocessable
tsoi-20220930_def.xml	Edgar Link	unprocessable
tsoi-20220930_lab.xml	Edgar Link	unprocessable
tsoi-20220930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TSOI
THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Stock $tsoi

2022 Q4 Form 10-Q Financial Statement

#000149315222032787 Filed on November 17, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TSOI THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Stock $tsoi

2022 Q4 Form 10-Q Financial Statement

#000149315222032787 Filed on November 17, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TSOI
THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Stock $tsoi